699851P
3A-MPLA
Manufacturer: Sigma Aldrich
CAS Number: 1699735-80-2
Synonym(S): Monophosphoryl Tri-acyl Lipid A (Synthetic)
Select a Size
| Pack Size | SKU | Availability | Price |
|---|---|---|---|
| 1 MG | 699851P-1-MG | In Stock | ₹ 3,63,200.40 |
699851P - 1 MG
In Stock
Quantity
1
Base Price: ₹ 3,63,200.40
GST (18%): ₹ 65,376.072
Total Price: ₹ 4,28,576.472
Assay
>99% (HPLC)
form
powder
packaging
pkg of 1 × 1 mg (699851P-1mg)pkg of 1 × 5 mg (699851P-5mg)
manufacturer/tradename
Avanti Polar Lipids 699851P
application(s)
vaccine development
shipped in
dry ice
storage temp.
−20°C
SMILES string
O[C@H]([C@@H](CO[C@@H]([C@@H]1NC(C[C@H](OC(CCCCCCCCCCCCC)=O)CCCCCCCCCCC)=O)O[C@H](CO)[C@@H](OP([O-])(O)=O)[C@@H]1O)O[C@H](O)[C@@H]2NC(C[C@H](O)CCCCCCCCCCC)=O)[C@@H]2O.[NH4+]
Related Products
Description
- General description: Monophosphoryl lipid A (MPLA) is an analog of the lipid A moiety.[1] It is regarded as a detoxified derivative of the lipopolysaccharide (LPS).[2]
- Biochem/physiol Actions: Monophosphoryl lipid A (MPLA) is a natural agonist for the toll-like receptor-4 (TLR4). It is useful as an adjuvant in immunization. MPLA is a safe prophylactic agent and has immunotherapeutic applications.[3] It induces tumor necrosis factor and interleukin (IL)-1β, however not as efficient as lipopolysaccharide (LPS). MPLA improves immune response during bacterial sepsis infection.
- Packaging: 2 mL Amber Glass Crimp Cap Vial (699851P-1mg)
- Other Notes: For R&D use only. Not for drug, household, or other uses.
SAFETY INFORMATION
WGK
WGK 3
Flash Point(F)
No data available
Flash Point(C)
No data available
Compare Similar Items
Show Difference
Assay: >99% (HPLC)
form: powder
packaging: pkg of 1 × 1 mg (699851P-1mg)pkg of 1 × 5 mg (699851P-5mg)
manufacturer/tradename: Avanti Polar Lipids 699851P
application(s): vaccine development
shipped in: dry ice
storage temp.: −20°C
SMILES string: O[C@H]([C@@H](CO[C@@H]([C@@H]1NC(C[C@H](OC(CCCCCCCCCCCCC)=O)CCCCCCCCCCC)=O)O[C@H](CO)[C@@H](OP([O-])(O)=O)[C@@H]1O)O[C@H](O)[C@@H]2NC(C[C@H](O)CCCCCCCCCCC)=O)[C@@H]2O.[NH4+]
Assay:
>99% (HPLC)
form:
powder
packaging:
pkg of 1 × 1 mg (699851P-1mg)pkg of 1 × 5 mg (699851P-5mg)
manufacturer/tradename:
Avanti Polar Lipids 699851P
application(s):
vaccine development
shipped in:
dry ice
storage temp.:
−20°C
SMILES string:
O[C@H]([C@@H](CO[C@@H]([C@@H]1NC(C[C@H](OC(CCCCCCCCCCCCC)=O)CCCCCCCCCCC)=O)O[C@H](CO)[C@@H](OP([O-])(O)=O)[C@@H]1O)O[C@H](O)[C@@H]2NC(C[C@H](O)CCCCCCCCCCC)=O)[C@@H]2O.[NH4+]
Assay: >99% (HPLC)
form: powder
packaging: pkg of 1 × 1 mg (699854P-1mg)pkg of 1 × 5 mg (699854P-5mg)
manufacturer/tradename: Avanti Polar Lipids
application(s): vaccine development
shipped in: dry ice
storage temp.: −20°C
SMILES string: O[C@H]([C@@H](CO[C@@H]([C@@H]1NC(C[C@H](OC(CCCCCCCCCCCCC)=O)CCCCCCCCCCC)=O)O[C@H](CO)[C@@H](OP([O-])(O)=O)[C@@H]1O)O[C@H](O)[C@@H]2NC(C[C@H](O)CCCCCCCCCCC)=O)[C@@H]2OC(C[C@H](O)CCCCCCCCCCC)=O.[NH4+]
Assay:
>99% (HPLC)
form:
powder
packaging:
pkg of 1 × 1 mg (699854P-1mg)pkg of 1 × 5 mg (699854P-5mg)
manufacturer/tradename:
Avanti Polar Lipids
application(s):
vaccine development
shipped in:
dry ice
storage temp.:
−20°C
SMILES string:
O[C@H]([C@@H](CO[C@@H]([C@@H]1NC(C[C@H](OC(CCCCCCCCCCCCC)=O)CCCCCCCCCCC)=O)O[C@H](CO)[C@@H](OP([O-])(O)=O)[C@@H]1O)O[C@H](O)[C@@H]2NC(C[C@H](O)CCCCCCCCCCC)=O)[C@@H]2OC(C[C@H](O)CCCCCCCCCCC)=O.[NH4+]
Assay: >99% (HPLC)
form: powder
packaging: pkg of 1 × 1 mg (699855P-1mg)pkg of 1 × 10 mg (699855P-10MG)pkg of 1 × 10 mg (699855P-25MG)pkg of 1 × 5 mg (699855P-5mg)
manufacturer/tradename: Avanti Polar Lipids
application(s): vaccine development
shipped in: dry ice
storage temp.: −20°C
SMILES string: O[C@H]([C@@H](CO[C@@H]([C@@H]1NC(C[C@H](OC(CCCCCCCCCCCCC)=O)CCCCCCCCCCC)=O)O[C@H](CO)[C@@H](OP([O-])(O)=O)[C@@H]1OC(C[C@H](OC(CCCCCCCCCCCCC)=O)CCCCCCCCCCC)=O)O[C@H](O)[C@@H]2NC(C[C@H](OC(CCCCCCCCCCCCC)=O)CCCCCCCCCCC)=O)[C@@H]2O.[NH4+]
Assay:
>99% (HPLC)
form:
powder
packaging:
pkg of 1 × 1 mg (699855P-1mg)pkg of 1 × 10 mg (699855P-10MG)pkg of 1 × 10 mg (699855P-25MG)pkg of 1 × 5 mg (699855P-5mg)
manufacturer/tradename:
Avanti Polar Lipids
application(s):
vaccine development
shipped in:
dry ice
storage temp.:
−20°C
SMILES string:
O[C@H]([C@@H](CO[C@@H]([C@@H]1NC(C[C@H](OC(CCCCCCCCCCCCC)=O)CCCCCCCCCCC)=O)O[C@H](CO)[C@@H](OP([O-])(O)=O)[C@@H]1OC(C[C@H](OC(CCCCCCCCCCCCC)=O)CCCCCCCCCCC)=O)O[C@H](O)[C@@H]2NC(C[C@H](OC(CCCCCCCCCCCCC)=O)CCCCCCCCCCC)=O)[C@@H]2O.[NH4+]
Assay: ≥99% (TLC)
form: powder
packaging: pkg of 1 × 10 mg (699856P-10MG)pkg of 1 × 5 mg (699856P-5MG)
manufacturer/tradename: Avanti Polar Lipids
application(s): vaccine development
shipped in: dry ice
storage temp.: −20°C
SMILES string: [Na+].[Na+].CCCCCCCCCCCC(=O)NC1[C@@H](OP([O-])([O-])=O)OC(CO)[C@@H](OC(=O)CCCCCCCCCCC)C1OC(=O)CCCCCCCCCCC
Assay:
≥99% (TLC)
form:
powder
packaging:
pkg of 1 × 10 mg (699856P-10MG)pkg of 1 × 5 mg (699856P-5MG)
manufacturer/tradename:
Avanti Polar Lipids
application(s):
vaccine development
shipped in:
dry ice
storage temp.:
−20°C
SMILES string:
[Na+].[Na+].CCCCCCCCCCCC(=O)NC1[C@@H](OP([O-])([O-])=O)OC(CO)[C@@H](OC(=O)CCCCCCCCCCC)C1OC(=O)CCCCCCCCCCC